{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:19:39Z","timestamp":1793233179074,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["213494\/Z\/18\/Z"],"award-info":[{"award-number":["213494\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["228185\/Z\/23\/Z"],"award-info":[{"award-number":["228185\/Z\/23\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["226727\/Z\/22\/Z"],"award-info":[{"award-number":["226727\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X020258\/1"],"award-info":[{"award-number":["MR\/X020258\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X020258\/1"],"award-info":[{"award-number":["MR\/X020258\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X020258\/1"],"award-info":[{"award-number":["MR\/X020258\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["NIHR200908"],"award-info":[{"award-number":["NIHR200908"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dengue is the most common arboviral infection, causing substantial morbidity and mortality globally. The licensing of Qdenga, a second-generation vaccine developed by Takeda Pharmaceuticals, is therefore timely, but the potential public health impact of vaccination across transmission settings needs to be evaluated. To address this, we characterized Qdenga\u2019s efficacy profile using mathematical models calibrated to published clinical trial data and estimated the public health impact of routine vaccine use. We find that efficacy against both virologically confirmed dengue and hospitalization depends on the infecting serotype, serological status and age. We estimate that vaccination of children aged over 6\u2009years in moderate-to-high dengue transmission settings (average seroprevalence in 9-year-olds &gt; 60%) could reduce the burden of hospitalized dengue by 10\u201322% on average over 10\u2009years. We find some evidence of a risk of vaccine-induced disease enhancement in seronegative vaccine recipients for dengue serotypes 3 and 4, especially for children under 6\u2009years of age. Because of this, the benefits of vaccination in lower transmission settings are more uncertain, and more data on the long-term efficacy of Qdenga against serotypes 3 and 4 are needed.<\/jats:p>","DOI":"10.1038\/s41591-025-03771-y","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:02:54Z","timestamp":1750827774000},"page":"2663-2672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Efficacy, public health impact and optimal use of the Takeda dengue vaccine"],"prefix":"10.1038","volume":"31","author":[{"given":"Bethan","family":"Cracknell Daniels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1154-8093","authenticated-orcid":false,"given":"Neil M.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-0706","authenticated-orcid":false,"given":"Ilaria","family":"Dorigatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"3771_CR1","doi-asserted-by":"publisher","unstructured":"Halstead, S. B. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol. Spectr. https:\/\/doi.org\/10.1128\/microbiolspec.aid-0022-2014 (2014).","DOI":"10.1128\/microbiolspec.aid-0022-2014"},{"key":"3771_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1084\/jem.146.1.201","volume":"146","author":"S Halstead","year":"1977","unstructured":"Halstead, S. & O\u2019Rourke, E. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146, 201\u2013217 (1977).","journal-title":"J. Exp. Med."},{"key":"3771_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","volume":"379","author":"S Sridhar","year":"2018","unstructured":"Sridhar, S. et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N. Engl. J. Med. 379, 327\u2013340 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3771_CR4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1126\/science.aaf9590","volume":"353","author":"NM Ferguson","year":"2016","unstructured":"Ferguson, N. M. et al. Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment. Science 353, 1033\u20131036 (2016).","journal-title":"Science"},{"key":"3771_CR5","doi-asserted-by":"publisher","first-page":"20130414","DOI":"10.1098\/rsif.2013.0414","volume":"10","author":"NG Reich","year":"2013","unstructured":"Reich, N. G. et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J. R. Soc. Interface 10, 20130414 (2013).","journal-title":"J. R. Soc. Interface"},{"key":"3771_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4269\/ajtmh.1952.1.30","volume":"1","author":"AB Sabin","year":"1952","unstructured":"Sabin, A. B. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1, 30\u201350 (1952).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"3771_CR7","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aan6836","volume":"358","author":"LC Katzelnick","year":"2017","unstructured":"Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929\u2013932 (2017).","journal-title":"Science"},{"key":"3771_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41586-018-0157-4","volume":"557","author":"H Salje","year":"2018","unstructured":"Salje, H. et al. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature 557, 719\u2013723 (2018).","journal-title":"Nature"},{"key":"3771_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1073\/pnas.1522136113","volume":"113","author":"LC Katzelnick","year":"2016","unstructured":"Katzelnick, L. C., Montoya, M., Gresh, L., Balmaseda, A. & Harris, E. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc. Natl Acad. Sci. USA 113, 728\u2013733 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3771_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44330-8","volume":"15","author":"S Bos","year":"2024","unstructured":"Bos, S. et al. Protection against symptomatic dengue infection by neutralizing antibodies varies by infection history and infecting serotype. Nat. Commun. 15, 382 (2024).","journal-title":"Nat. Commun."},{"key":"3771_CR11","doi-asserted-by":"publisher","first-page":"e2952","DOI":"10.1371\/journal.pntd.0002952","volume":"8","author":"H Salje","year":"2014","unstructured":"Salje, H. et al. Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development. PLoS Negl. Trop. Dis. 8, e2952 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"3771_CR12","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/infdis\/jix609","volume":"217","author":"Z Moodie","year":"2018","unstructured":"Moodie, Z. et al. Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America. J. Infect. Dis. 217, 742\u2013753 (2018).","journal-title":"J. Infect. Dis."},{"key":"3771_CR13","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41591-021-01392-9","volume":"27","author":"H Salje","year":"2021","unstructured":"Salje, H. et al. Evaluation of extended efficacy of Dengvaxia vaccine against symptomatic and subclinical dengue infection. Nat. Med. 27, 1395\u20131400 (2021).","journal-title":"Nat. Med."},{"key":"3771_CR14","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1016\/j.vaccine.2018.02.062","volume":"36","author":"KS Vannice","year":"2018","unstructured":"Vannice, K. S. et al. Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. Vaccine 36, 3411\u20133417 (2018).","journal-title":"Vaccine"},{"key":"3771_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0140-6736(24)00046-1","volume":"403","author":"L Alves","year":"2024","unstructured":"Alves, L. Brazil to start widespread dengue vaccinations. Lancet 403, 133 (2024).","journal-title":"Lancet"},{"key":"3771_CR16","doi-asserted-by":"publisher","first-page":"7112","DOI":"10.1016\/j.vaccine.2015.11.022","volume":"33","author":"JE Osorio","year":"2015","unstructured":"Osorio, J. E., Partidos, C. D., Wallace, D. & Stinchcomb, D. T. Development of a recombinant, chimeric tetravalent dengue vaccine candidate. Vaccine 33, 7112\u20137120 (2015).","journal-title":"Vaccine"},{"key":"3771_CR17","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","volume":"381","author":"S Biswal","year":"2019","unstructured":"Biswal, S. et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N. Engl. J. Med. 381, 2009\u20132019 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3771_CR18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","volume":"395","author":"S Biswal","year":"2020","unstructured":"Biswal, S. et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316\u2009years: a randomised, placebo-controlled, phase 3 trial. Lancet 395, 1423\u20131433 (2020).","journal-title":"Lancet"},{"key":"3771_CR19","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","volume":"225","author":"E L\u00f3pez-Medina","year":"2022","unstructured":"L\u00f3pez-Medina, E. et al. Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2\u2009years after vaccination. J. Infect. Dis. 225, 1521\u20131532 (2022).","journal-title":"J. Infect. Dis."},{"key":"3771_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/cid\/ciab864","volume":"75","author":"L Rivera","year":"2022","unstructured":"Rivera, L. et al. Three-year efficacy and safety of Takeda\u2019s dengue vaccine candidate (TAK-003). Clin. Infect. Dis. 75, 107\u2013117 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"3771_CR21","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","volume":"12","author":"V Tricou","year":"2024","unstructured":"Tricou, V. et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob. Health 12, e257\u2013e270 (2024).","journal-title":"Lancet Glob. Health"},{"key":"3771_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009258","volume":"15","author":"LJ White","year":"2021","unstructured":"White, L. J. et al. Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003). PLoS Negl. Trop. Dis. 15, e0009258 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"3771_CR23","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3389\/fimmu.2019.01778","volume":"10","author":"AT Waickman","year":"2019","unstructured":"Waickman, A. T. et al. Assessing the diversity and stability of cellular immunity generated in response to the candidate live-attenuated dengue virus vaccine TAK-003. Front. Immunol. 10, 1778 (2019).","journal-title":"Front. Immunol."},{"key":"3771_CR24","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.vaccine.2022.01.016","volume":"40","author":"V Tricou","year":"2022","unstructured":"Tricou, V. et al. Characterization of the cell-mediated immune response to Takeda\u2019s live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting. Vaccine 40, 1143\u20131151 (2022).","journal-title":"Vaccine"},{"key":"3771_CR25","unstructured":"WHO Meeting of the strategic advisory group of experts on immunization, September 2023: conclusions and recommendations. Wkly Epidemiol. Rec. 98, 599\u2013620 (2023)."},{"key":"3771_CR26","unstructured":"WHO WHO position paper on dengue vaccines\u2014May 2024 Wkly Epidemiol. Rec. 99, 203\u2013224 (2024)."},{"key":"3771_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"3771_CR28","first-page":"jiaf145","volume":"18","author":"T El Hindi","year":"2025","unstructured":"El Hindi, T. et al. Estimated efficacy of TAK-003 against asymptomatic dengue infection in children and adolescents participating in the DEN-301 trial in Asia Pacific and Latin America. J. Infect. Dis. 18, jiaf145 (2025).","journal-title":"J. Infect. Dis."},{"key":"3771_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00593-24","volume":"62","author":"FA Medina","year":"2024","unstructured":"Medina, F. A. et al. Comparison of the sensitivity and specificity of commercial anti-dengue virus IgG tests to identify persons eligible for dengue vaccination. J. Clin. Microbiol. 62, e00593-24 (2024).","journal-title":"J. Clin. Microbiol."},{"key":"3771_CR30","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","volume":"14","author":"JE Osorio","year":"2014","unstructured":"Osorio, J. E. et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect. Dis. 14, 830\u2013838 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"3771_CR31","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65131","volume":"10","author":"DJ Laydon","year":"2021","unstructured":"Laydon, D. J. et al. Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data. eLife 10, e65131 (2021).","journal-title":"eLife"},{"key":"3771_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06006-6","volume":"9","author":"I Dorigatti","year":"2018","unstructured":"Dorigatti, I. et al. Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning. Nat. Commun. 9, 3644 (2018).","journal-title":"Nat. Commun."},{"key":"3771_CR33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1586\/erv.10.41","volume":"9","author":"KL Flanagan","year":"2010","unstructured":"Flanagan, K. L., Burl, S., Lohman-Payne, B. L. & Plebanski, M. The challenge of assessing infant vaccine responses in resource-poor settings. Expert Rev. Vaccines 9, 665\u2013674 (2010).","journal-title":"Expert Rev. Vaccines"},{"key":"3771_CR34","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","volume":"281","author":"JW Tappero","year":"1999","unstructured":"Tappero, J. W. et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281, 1520\u20131527 (1999).","journal-title":"JAMA"},{"key":"3771_CR35","unstructured":"PAHO Technical Advisory Group (TAG) on Immunization Provides Regional Recommendations on Vaccines Against Dengue, Respiratory Syncytial Virus, and Issues Statement on Ongoing Use of COVID-19 Vaccines (PAHO (Pan American Health Organization)\/WHO (World Health Organization), 2023); https:\/\/www.paho.org\/en\/news\/11-1-2024-paho-technical-advisory-group-tag-immunization-provides-regional-recommendations"},{"key":"3771_CR36","doi-asserted-by":"publisher","first-page":"eaax4144","DOI":"10.1126\/scitranslmed.aax4144","volume":"12","author":"L Cattarino","year":"2020","unstructured":"Cattarino, L., Rodriguez-Barraquer, I., Imai, N., Cummings, D. A. T. & Ferguson, N. M. Mapping global variation in dengue transmission intensity. Sci. Transl. Med. 12, eaax4144 (2020).","journal-title":"Sci. Transl. Med."},{"key":"3771_CR37","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1016\/j.vaccine.2018.04.022","volume":"37","author":"World Health Organization","year":"2019","unstructured":"World Health Organization Dengue vaccine: WHO position paper, September 2018 \u2013 recommendations. Vaccine 37, 4848\u20134849 (2019).","journal-title":"Vaccine"},{"key":"3771_CR38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S1473-3099(18)30799-0","volume":"19","author":"I Rodr\u00edguez-Barraquer","year":"2019","unstructured":"Rodr\u00edguez-Barraquer, I., Salje, H. & Cummings, D. A. Dengue pre-vaccination screening and positive predictive values. Lancet Infect. Dis. 19, 132\u2013134 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"3771_CR39","doi-asserted-by":"publisher","first-page":"7343","DOI":"10.1016\/j.vaccine.2022.10.071","volume":"40","author":"E Thommes","year":"2022","unstructured":"Thommes, E. et al. Public health impact and cost-effectiveness of implementing a \u2018pre-vaccination screening\u2019 strategy with the dengue vaccine in Puerto Rico. Vaccine 40, 7343\u20137351 (2022).","journal-title":"Vaccine"},{"key":"3771_CR40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41577-019-0123-x","volume":"19","author":"AL St. John","year":"2019","unstructured":"St. John, A. L. & Rathore, A. P. S. Adaptive immune responses to primary and secondary dengue virus infections. Nat. Rev. Immunol. 19, 218\u2013230 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"3771_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001311","volume":"5","author":"KB Anderson","year":"2011","unstructured":"Anderson, K. B. et al. Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand. PLoS Negl. Trop. Dis. 5, e1311 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"3771_CR42","doi-asserted-by":"publisher","first-page":"eabg9478","DOI":"10.1126\/scitranslmed.abg9478","volume":"13","author":"LC Katzelnick","year":"2021","unstructured":"Katzelnick, L. C. et al. Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term. Sci. Transl. Med. 13, eabg9478 (2021).","journal-title":"Sci. Transl. Med."},{"key":"3771_CR43","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.abb6143","volume":"369","author":"LC Katzelnick","year":"2020","unstructured":"Katzelnick, L. C. et al. Zika virus infection enhances future risk of severe dengue disease. Science 369, 1123\u20131128 (2020).","journal-title":"Science"},{"key":"3771_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn2199","volume":"16","author":"JV Zambrana","year":"2024","unstructured":"Zambrana, J. V. et al. Primary exposure to Zika virus is linked with increased risk of symptomatic dengue virus infection with serotypes 2, 3, and 4, but not 1. Sci. Transl. Med. 16, eadn2199 (2024).","journal-title":"Sci. Transl. Med."},{"key":"3771_CR45","doi-asserted-by":"publisher","first-page":"e1214","DOI":"10.1093\/infdis\/jiae222","volume":"230","author":"C Sirivichayakul","year":"2024","unstructured":"Sirivichayakul, C. et al. Efficacy and safety of a tetravalent dengue vaccine (TAK-003) in children with prior Japanese encephalitis or yellow fever vaccination. J. Infect. Dis. 230, e1214\u2013e1225 (2024).","journal-title":"J. Infect. Dis."},{"key":"3771_CR46","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2301790","volume":"390","author":"EG Kall\u00e1s","year":"2024","unstructured":"Kall\u00e1s, E. G. et al. Live, attenuated, tetravalent Butantan\u2013dengue vaccine in children and adults. N. Engl. J. Med. 390, 397\u2013408 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3771_CR47","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1056\/NEJMoa2030243","volume":"384","author":"A Utarini","year":"2021","unstructured":"Utarini, A. et al. Efficacy of Wolbachia-infected mosquito deployments for the control of dengue. N. Engl. J. Med. 384, 2177\u20132186 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3771_CR48","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41586-023-05790-6","volume":"615","author":"O Goethals","year":"2023","unstructured":"Goethals, O. et al. Blocking NS3\u2013NS4B interaction inhibits dengue virus in non-human primates. Nature 615, 678\u2013686 (2023).","journal-title":"Nature"},{"key":"3771_CR49","doi-asserted-by":"publisher","first-page":"e0234236","DOI":"10.1371\/journal.pone.0234236","volume":"15","author":"LN Carpp","year":"2020","unstructured":"Carpp, L. N. et al. Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. PLoS One 15, e0234236 (2020).","journal-title":"PLoS One"},{"key":"3771_CR50","unstructured":"Gabry, J. et al. cmdstanr: R Interface to \u2018CmdStan\u2019. R package version 0.9.0 https:\/\/mc-stan.org\/cmdstanr\/ (2025)."},{"key":"3771_CR51","unstructured":"R Core Team R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2024)."},{"key":"3771_CR52","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1214\/ss\/1177011136","volume":"7","author":"A Gelman","year":"1992","unstructured":"Gelman, A. & Rubin, D. B. Inference from iterative simulation using multiple sequences. Stat. Sci. 7, 457\u2013472 (1992).","journal-title":"Stat. Sci."},{"key":"3771_CR53","unstructured":"World Population Prospects (United Nations, 2022); https:\/\/www.un.org\/development\/desa\/pd\/content\/World-Population-Prospects-2022"},{"key":"3771_CR54","doi-asserted-by":"publisher","first-page":"11-8","DOI":"10.4269\/ajtmh.2000.62.11","volume":"62","author":"DA Focks","year":"2000","unstructured":"Focks, D. A. et al. Transmission thresholds for dengue in terms of Aedes aegypti pupae per person with discussion of their utility in source reduction efforts. Am. J. Trop. Med. Hyg. 62, 11-8 (2000).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"3771_CR55","doi-asserted-by":"publisher","first-page":"e0003719","DOI":"10.1371\/journal.pntd.0003719","volume":"9","author":"N Imai","year":"2015","unstructured":"Imai, N., Dorigatti, I., Cauchemez, S. & Ferguson, N. M. Estimating dengue transmission intensity from sero-prevalence surveys in multiple countries. PLoS Negl. Trop. Dis. 9, e0003719 (2015).","journal-title":"PLoS Negl. Trop. Dis."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03771-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03771-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03771-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:11:29Z","timestamp":1757196689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03771-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3771"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03771-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}